Why promoter design is no longer just an expression checkbox, it’s the key to therapeutic endurance:
Advanced therapies Why promoter design is no longer just an expression checkbox, it’s the key…
27 July 2026
The development of cell and gene therapies is a complex and time-consuming process that depends on therapeutic genes being expressed in the right tissues, at the right time and at the right dosage. A key challenge lies in identifying and optimizing promoters and enhancers that precisely control transgene expression in target cells and which do not get silenced over time as seen for example for viral promoters. Conventional methods to generate novel promoters by rational design lacks throughput in both design and subsequent validation and novel computational design approaches still need to address the challenge of high-throughput real-life validation.
Annogen’s SuRE™ (Survey of Regulatory Elements) platform is a massively parallel reporter assay designed to expedite the discovery and optimization of gene promoters and enhancers critical for the success of cell and gene therapies. By providing a comprehensive solution for identifying, characterizing, and engineering optimal promoters, SuRE™ empowers researchers to develop safer, more effective, and durable therapeutic products.
SuRE™ has a broad range of applications in cell and gene therapy development, including:
Our team of experts is dedicated to supporting your research and development efforts, as we have done for numerous top biopharmaceutical companies before. We offer a range of services, including custom promoter identification and optimization, licensing opportunities for our proprietary promoters, as well as custom identification of favorable transgene integration sites.
